Genmab — Februar 2018
-
Det samme ser vi vist også fra ENS.
-
Dara-kombi første-valg efter første relaps. Må snart kunne aflæses i salgstallene. https://www.youtube.com/watch?v=xpZwjoP5GT8
-
havde vi ikke kun 20% andel af anden linje og 40% af tredje linje med Pom, sidste gang der blev snakket penetration??
-
God morgen.

-
"Same procedure as last year". Vi får en forsigtig guiding med et spænd mellem min. salg og max salg.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind